The following statement are as follows:
• Dopamine dysregulation Syndrome (DDS) is an addictive disorder resulting in excessive use of the product seen in some patients treated with dopaminergic medications, including pramipexole. Before initiation of treatment, patients and caregivers should be warned of the potential risk of developing DDS.
• Dopamine agonist withdrawal syndrome: To discontinue treatment in patients with Parkinson's disease, pramipexole should be tapered off. Non-motor adverse effects may occur when tapering or discontinuing dopamine agonists including pramipexole. Symptoms include apathy, anxiety, depression, fatigue, sweating and pain which may be severe. Patients should be informed about this before tapering the dopamine agonist, and monitored regularly thereafter. In case of persistent symptoms, it may be necessary to increase the pramipexole dose temporarily.